Endometrial Cancer
Conditions
Brief summary
Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.
Interventions
DIAGNOSTIC_TESTketohexokinase
Check the isoforms of ketohexokinase in the specimen of endometrial cancer
Sponsors
Gynecologic Oncology Group
Far Eastern Memorial Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>20 years * Women with endometrial cancer who are about to be admitted to hospital for gynecological staging. * Women who have undergone gynecological staging surgery for endometrial cancer in the past.
Exclusion criteria
* Women with endometrial cancer who receive preoperative chemotherapy or radiation therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The role of ketohexokinase isoforms in the overall survival of endometrial cancer. | 5 years | Cox proportional hazard regression to evaluate the role of ketohexokinase isoforms in the overall survival of endometrial cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of ketohexokinase isoforms with the other prognostic risk factors | 5 years | Correlation of ketohexokinase isoforms with deep myometrial invasion, tumor grade, lymph node metastasis, FIGO stage, tumor size, progression-free survival, etc. |
Countries
Taiwan
Contacts
Primary ContactSheng-Mou Hsiao, MD
Outcome results
None listed